POSITIVELY PRECISE.

We’re developing targeted therapies to lower LDL cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More

Pipeline

Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, complementary, once-daily, oral, LDL-C lowering therapies for the treatment of patients with elevated LDL-C.

learn more

HEARTS & MINDS BLOG

Resilient and Relentlessly Focused in 2017

Happy New Year! We welcomed 2017 with tremendous momentum as we advanced our bempedoic acid (ETC-1002) pivotal Phase 3 LDL… more

Posted by Lesley Martin

Bempedoic Acid Mechanism of Action Paper Published in Nature Communications: Q&A with the Authors

As you may have seen, Esperion scientists and collaborators recently published the definitive paper on the mechanism of action for… more

Posted by Mindy Lowe

The History of LDL-Cholesterol with Dr. Antonio Gotto

As you know, Esperion is focused on developing and commercializing therapies for the treatment of patients with hypercholesterolemia who are… more

Posted by Mindy Lowe